Quarterly ResultMay 7, 2026, 08:58 AM
InspireMD Q1 Revenue +122% to $3.4M; Going Concern Doubt
AI Summary
InspireMD reported a significant 122% increase in Q1 2026 revenue to $3.398 million, but its net loss widened to $13.689 million. The company disclosed substantial doubt about its ability to continue as a going concern due to a history of losses and negative operating cash flows. Additionally, subsequent to the quarter, InspireMD announced a voluntary recall of its CGuard Prime 135 cm carotid stent delivery system in the U.S., estimating $1.35 million in related reserves for customer returns and inventory impairment.
Key Highlights
- Substantial doubt about InspireMD's ability to continue as a going concern due to recurring losses and negative cash flows.
- Voluntary recall of CGuard Prime 135 cm delivery system announced post-quarter, with $1.35 million estimated reserves.
- Q1 2026 revenue increased 122% to $3.398 million from $1.529 million year-over-year.
- Net loss widened to $13.689 million in Q1 2026 from $11.166 million in Q1 2025.
- Net loss per share improved to $(0.16) in Q1 2026 from $(0.22) in Q1 2025.
- Net cash used in operating activities increased to $12.337 million from $8.792 million.
- Cash and cash equivalents increased to $11.362 million as of March 31, 2026.
- Completed enrollment in the CGUARDIANS II pivotal study during Q1 2026.
Price Impact
More from NSPR